Non-small cell lung cancer advances in China in August 2020.

Wendy Ryals, an ordinary American farmer and lung cancer survivor, had dreamed of saving enough money one day to help the homeless.
one night, Wendy started coughing and coughing up a little blood, and she went back to the clinic, where doctors sent her for X-rays showing a large 10.5cm lump in her left lung.
February 2017, a biopsy confirmed that she had non-small cell lung cancer.
Because of the type and stage of Wendy's cancer, doctors recommend an immunotherapy treatment, a newer drug that targets a protein on the surface of T cells and may shrink some tumors.
year after taking the drug, scans showed her tumour was getting smaller and smaller.
, she told reporters: "She's doing fine, but she's worried about everyone else."
She hopes that the rich and the poor, regardless of age, color, rich or poor, can unite to fight this disease, whether it is for those they love or don't even know;
" lung cancer morbidity and mortality rate are among the highest, of which non-small cell lung cancer accounted for 80%-85%.
Sceasly, new technologies and products may work for some people, but different lung cancer patients may have different "bad" genetic mutations or other pathological conditions, so scientists are constantly developing new drugs to meet the needs of patients with non-small cell lung cancer (NSCLC) in different situations.
this paper will organize the development of new drugs for the treatment of non-small cell lung cancer in China in August 2020 for your reference.
, January and August NSCLC new drug research and development progress in China: According to incomplete statistics, in August 2020 in China, there are the following five targeted drugs landmark progress.
August 26, the keystone pharmaceutical RET inhibitor Platini capsules (pralsetinib capsules) are to be included in the list of priority review varieties for the treatment of RET fusion-positive NSCLC patients with platinum-containing chemotherapy.
Pralsetinib is a powerful, highly selective, targeted cancer-causing RET variant, including predictable drug-resistant mutations, developed by Blueprint Pharmaceuticals, a strategic partner of Keystone Pharmaceuticals, which was granted exclusive development and commercialization license in June 2018.
the United States, the drug was recently approved for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) adult patients, based on DATA from PHASE 1/2 clinical trial ARROW.
August 16th, Corning Jerry announced the launch of its phase 3 clinical trial of dual-specific antibody KN046 combined with platinum-containing chemotherapy in contrast to placebo-containing placebo in patients with stage IV squamous non-small cell lung cancer, and the launch of the KN046-301 (registration number CTR20201294) study is a The randomized, double-blind, placebo-controlled trial, led by Professor Zhou Caishuang of Shanghai Lung Hospital, will be conducted in about 60 research centers and plans to recruit about 500 volunteers to assess the safety and effectiveness of combined chemotherapy at KN046-5 mg doses, with the main endpoint being IRC's disease-free progression survival based on the RECIST 1.1 standard.
"KN046 is the world's first PD-L1/CTLA-4 dual-specific antibody, and this Phase 3 clinical trial will be used to declare A new drug in China," said Dr. Xu Wei, founder, chairman and president of CorningErry.
August 12, Cyntharma bio and Lilly jointly announced that the National Drug Administration (NMPA) has officially accepted the innovative PD-1 inhibitor Dabershu® Prior to the application for new adaptations for scaly NSCLC first-line treatment, NMPA formally accepted the application for new adaptive conditions for non-scaly NSCLC first-line treatment on 23 April 2020 by Dabershu ® (Syndili monoantigen injection).
August 6, Keystone Pharmaceuticals announced that its PD-L1 Shugli monoantigen (CS1001) injection combination chemotherapy demonstrated good results in a randomized double-blind Phase 3 clinical trial for first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC), which reached the preset main research endpoint by the Independent Data Monitoring Board (iDMC).
Pharmaceuticals plans to submit to China's State Drug Administration (NMPA) a new drug for CS1001 combined chemotherapy first-line treatment of NSCLC adaptation.
also said that Shugli monoantigen is expected to become the world's first combined chemotherapy approved scaly and non-scaly NSCLC first-line treatment of anti-PD-L1 monoantigen.
NSCLC clinical trials recruited in China in February and August, ClinicalTrials shows more than 300 NSCLC clinical trials recruited in China, and the table below lists 24 new NSCLC drug clinical trials recruited in China (newly registered and updated in August).
3, August by the CDE clinical implied approval of the new NSCLC drug before entering human clinical trials, there are compound design, cell testing, animal model testing (preclinical trial) and other work, in China, only by the State Drug Administration Drug Review Center (CDE) clinical implied permission to carry out human clinical trials.
CDE Clinical Implied Licensing website was approved in August for the treatment of non-small cell lung cancer new drugs as shown in the table below: August 28, Roche developed TIGIT inhibitor tiragolumab injection obtained clinical implied approval, intended to be used in the combined arterial bead monoantitherapy previously untreated local late stage, non-excisive or metastasis PD-L1 high expression non-small cell lung cancer.
TIGIT is an inhibitory subject that is highly expressed in tumor-immersed T-cells of multiple cancer types and inhibits the activation of T-cells by binding to CD226 competition and PPR, disrupting the activation of CD226.
, a number of enterprises have invested in TIGIT antibody research and development, approved clinical IBI939 and Baiji Shenzhou BGB-A1217.
, August 19th, Dizhe Pharmaceuticals completed a $100 million round of A financing to develop an EGFR inhibitor (DZD9008) for the treatment of carrying EGFR or HER2 genes. 20 exon insertion mutation or other driving mutation of non-small cell lung cancer patients;
August 18, Xinhua Bio and Lilly Pharmaceuticals jointly announced that they will expand their strategic cooperation on the immuno-oncology drug anti-PD-1 monoclonal antibody Dabershu (Xindili monoanti) and that the new cooperation will expand to the global market.
the agreement, Lilly will receive exclusive licenses from Xindi lisan resistance outside China, and Thyda Bio will receive a cumulative total of more than $1 billion.
Xindili monoantigen was approved in China at the end of 2018 for the treatment of relapsed/refractic classic Hodgkin's lymphoma, is the first PD-1 inhibitor to enter China's national health insurance catalog, and its application for the first-line treatment of squamous and non-scaly NSCLC is currently being reviewed and approved by the State Drug Administration of China.
5. Conclusion New drug research and development is a long time, multi-sectoral, multi-professional cooperation of a step-by-step work, only research and development, quality inspection, investment and financing, supervision and other professionals together, in order to better overcome non-small cell lung cancer and other diseases endangering human health, immediate drug news will continue to pay attention to the development of these major diseases progress.
: This article is intended to introduce advances in medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: [1] [2] [3] #